Besifloxacin ophthalmic suspension 0.6% (Bausch & Lomb) has been recommended by the FDA for the treatment of bacterial conjunctivitis.
Besifloxacin ophthalmic suspension 0.6% (Bausch & Lomb) has been recommended by the FDA for the treatment of bacterial conjunctivitis.
Besifloxacin, a broad-spectrum fluoroquinolone anti-microbial agent, works by inhibiting inflammation in THP-1 monocytes.
The FDA recommendation is a step towards final approval; if approved, Bausch & Lomb aims to bring besifloxacin to the market next year.
ARxVision, Seeing AI, NaviLens announce partnership for headset programme
April 1st 2024The UK's Royal National Institute of Blind People is the global distributor of the headset and ARxVision is partnering with the National Federation of the Blind and Vision Australia to expand global accessibility